GlobeSt.com discussed the real estate aspects of the acquisitionwith Rebecca Hamm, a spokesperson with Amgen, headquartered inThousand Oaks, CA. GlobeSt.com was unable to reach Immunexofficials for comment, as its executive offices are closed untilafter New Year's Day.

Hamm confirms that after closing sometime in late 2002, thecompany plans to retain both Immunex's Rhode Island factories andthe $750-million Helix Project, a new headquarters campus underconstruction at Terminal 88 in Seattle's Interbay area.

Ground was broken last March on the first phase of the massiveHelix development. When completed sometime in late 2003, the campuswill contain 1.3 million sf in seven buildings, including 828,000sf of offices and laboratories. Prior to the deal with Amgen,Immunex had foreseen the potential development of the entire29-acre site, depending upon the extent company's growth.